Route 92 Medical Scores $31 Million Series F

<p><strong>SAN MATEO<&sol;strong> &&num;8212&semi; Route 92 Medical&comma; Inc&period;&comma; a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention&comma; has raised over &dollar;31 million in a Series F financing to accelerate the commercial adoption of a neurovascular intervention portfolio focused on acute ischemic stroke&period; The oversubscribed capital raise was led by existing venture capital investors&colon; U&period;S&period; Venture Partners&comma; Norwest Venture Partners&comma; InnovaHealth Partners&comma; and The Vertical Group&period;<&sol;p>&NewLine;<p>Route 92 Medical has reimagined neurovascular intervention through the development of a suite of reperfusion systems leveraging unique designs including the Tenzing delivery catheter&period; These products are designed to work harmoniously as a system to improve the efficiency of endovascular thrombectomy procedures&comma; enabling clinicians to quickly restore blood flow to a patient’s brain following acute ischemic stroke&comma; the most common type of stroke affecting patients today&period;<&sol;p>&NewLine;<p>Proceeds from the financing will be used to accelerate the U&period;S&period; commercialization of the FreeClimb<sup> <&sol;sup>70 Reperfusion system featuring the FreeClimb 70 aspiration catheter and the Tenzing 7 delivery catheter&period; Funds will also be used to complete SUMMIT MAX&comma; an FDA IDE-approved pivotal trial evaluating the HiPoint 88 and HiPoint 70 catheter systems&comma; both featuring the Tenzing delivery catheter&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The launch of the first complete reperfusion system with the Tenzing delivery approach is a tremendous step forward for stroke care&comma;” said Chris Hartman&comma; Chief Commercial Officer of Route 92 Medical&period; &OpenCurlyDoubleQuote;We have already seen early clinical adoption as the Route 92 organization continues to execute on many fronts&colon; product development and regulatory milestones&comma; scaling manufacturing capabilities&comma; hiring world-class sales personnel&comma; and growing commercial operations&period;”<&sol;p>&NewLine;<p>The funds will also support the company’s operational growth&period; Route 92 Medical is completing the process validations of its first commercially available products from its new high-volume manufacturing plant near Salt Lake City&comma; UT&period; The new 40&comma;000 square foot facility will provide over 12&comma;000 square feet of production clean room&comma; warehousing&comma; and distribution functions with enough stand-alone capacity to fulfill the growing demand for the Company’s products well into the future&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are continuing to build our industry-leading commercial and support teams to bring our Tenzing&comma; FreeClimb&comma; HiPoint&comma; and Monopoint products to the market&comma; serving our interventionalist customers and their patients&period; This latest investment validates our clinical and commercial performance as we focus on improving outcomes for patients suffering from devastating strokes&comma;” said Tony Chou&comma; Chief Executive Officer and Founder at Route 92 Medical&period;<&sol;p>&NewLine;